Skip to main content
Erschienen in: International Urology and Nephrology 2/2014

01.02.2014 | Urology - Original Paper

Emergency hospital admissions attributable to infective complications of prostate biopsy despite appropriate prophylaxis: need for additional infection prevention strategies?

verfasst von: G. Gopal Rao, Deepak Batura

Erschienen in: International Urology and Nephrology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To report the incidence of emergency admissions attributable to infective complications of transrectal ultrasound-guided prostate biopsy (TGB) and evaluate appropriateness of antimicrobial prophylaxis.

Methods

Retrospective cross-sectional study of patients undergoing TGB at the North West London Hospitals in 2009–2011. Demographic information of patients who had emergency admission within 30 days of TGB, length of hospital stay and microbiology results were obtained from the hospital’s information system, medical records and laboratory information system. All patients received ciprofloxacin and amikacin prophylaxis.

Results

1,419 TGB were performed in 1,276 patients. Forty-eight (3.3 %) patients had emergency admissions. Thirty-three (2.3 %) admissions were due to complications from TGB, while 15 (1 %) were for unrelated reasons. 30/33 (90 %, overall 2.1 %) of admissions from TGB complications were due to confirmed infections or systemic inflammatory response syndrome (SIRS). The rest were admitted with urinary retention. Admission rates due to TGB complications and infection/SIRS remained consistent over the 3 years (2009: TGB complications—2 %, TGB infection/SIRS—1.8 %; 2010: TGB complications—2.4 %, TGB infections/SIRS—2.2 %; 2011: TGB complications—2.6 %, TGB infection/SIRS—2.4 %; P > 0.05). All 11 cases with bacteraemia were caused by ciprofloxacin-resistant but amikacin-susceptible E. coli.

Conclusions

We observed a consistent rate of emergency admissions for complications following TGB; 90 % of these were due to infections. Ciprofloxacin-resistant but amikacin-sensitive E. coli was isolated in all bacteriologically confirmed infections. These results suggest that infective complications of TGB cannot be altogether eliminated despite appropriate antimicrobial prophylaxis. Therefore, additional strategies for reduction in biopsy-related admissions due to infections have to be considered.
Literatur
1.
Zurück zum Zitat Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA (2010) Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183:963–968PubMedCrossRef Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA (2010) Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183:963–968PubMedCrossRef
2.
Zurück zum Zitat Zlotta AR, Nam RK (2012) To biopsy or not to biopsy—thou shall think twice. Eur Urol 61:1115–1117PubMedCrossRef Zlotta AR, Nam RK (2012) To biopsy or not to biopsy—thou shall think twice. Eur Urol 61:1115–1117PubMedCrossRef
3.
Zurück zum Zitat Loeb S, van Den HS, Zhu X, Bangma CH, Schroder FH, Roobol MJ (2012) Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 61:1110–1114PubMedCrossRef Loeb S, van Den HS, Zhu X, Bangma CH, Schroder FH, Roobol MJ (2012) Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 61:1110–1114PubMedCrossRef
4.
Zurück zum Zitat Wagenlehner FM, Van OE, Tenke P, Tandogdu Z, Cek M, Grabe M, Wullt B, Pickard R, Naber KG, Pilatz A, Weidner W, Bjerklund-Johansen TE (2012) Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 63:521–527PubMedCrossRef Wagenlehner FM, Van OE, Tenke P, Tandogdu Z, Cek M, Grabe M, Wullt B, Pickard R, Naber KG, Pilatz A, Weidner W, Bjerklund-Johansen TE (2012) Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 63:521–527PubMedCrossRef
5.
Zurück zum Zitat Batura D, Gopal Rao G (2013) The national burden of infections after prostate biopsy in England and Wales: a wake-up call for better prevention. J Antimicrob Chemother 68:247–249PubMedCrossRef Batura D, Gopal Rao G (2013) The national burden of infections after prostate biopsy in England and Wales: a wake-up call for better prevention. J Antimicrob Chemother 68:247–249PubMedCrossRef
6.
Zurück zum Zitat Patel U, Dasgupta P, Amoroso P, Challacombe B, Pilcher J, Kirby R (2012) Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use. BJU Int 109:1781–1785PubMedCrossRef Patel U, Dasgupta P, Amoroso P, Challacombe B, Pilcher J, Kirby R (2012) Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use. BJU Int 109:1781–1785PubMedCrossRef
7.
Zurück zum Zitat Ganeswaran D, Sweeney C, Yousif F, Lang S, Goodman C, Nabi G (2012) Population-based linkage of health records to detect urological complications and hospitalisation following transrectal ultrasound-guided biopsies in men suspected of prostate cancer. World J Urol (Epub ahead of print). doi:10.1007/s00345-012-0893-2 Ganeswaran D, Sweeney C, Yousif F, Lang S, Goodman C, Nabi G (2012) Population-based linkage of health records to detect urological complications and hospitalisation following transrectal ultrasound-guided biopsies in men suspected of prostate cancer. World J Urol (Epub ahead of print). doi:10.​1007/​s00345-012-0893-2
8.
Zurück zum Zitat Livermore DM, James D, Reacher M, Graham C, Nichols T, Stephens P, Johnson AP, George RC (2002) Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990–1999. Emerg Infect Dis 8:473–478PubMedCrossRef Livermore DM, James D, Reacher M, Graham C, Nichols T, Stephens P, Johnson AP, George RC (2002) Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990–1999. Emerg Infect Dis 8:473–478PubMedCrossRef
9.
Zurück zum Zitat Batura D, Gopal Rao G, Nielsen PB (2010) Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJU Int 106:1017–1020PubMedCrossRef Batura D, Gopal Rao G, Nielsen PB (2010) Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJU Int 106:1017–1020PubMedCrossRef
10.
Zurück zum Zitat Andrews JM (2009) BSAC standardized disc susceptibility testing method (version 8). J Antimicrob Chemother 64:454–489PubMedCrossRef Andrews JM (2009) BSAC standardized disc susceptibility testing method (version 8). J Antimicrob Chemother 64:454–489PubMedCrossRef
11.
Zurück zum Zitat Livermore DM, Hawkey PM (2005) CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 56:451–454PubMedCrossRef Livermore DM, Hawkey PM (2005) CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 56:451–454PubMedCrossRef
12.
Zurück zum Zitat Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald W (2009) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 136(5 Suppl):e28 Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald W (2009) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 136(5 Suppl):e28
13.
Zurück zum Zitat Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM (2011) Complications after prostate biopsy: data from SEER-Medicare. J Urol 186:1830–1834PubMedCrossRef Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM (2011) Complications after prostate biopsy: data from SEER-Medicare. J Urol 186:1830–1834PubMedCrossRef
14.
Zurück zum Zitat Sanders A, Buchan N (2013) Infection-related hospital admissions after transrectal biopsy of the prostate. ANZ J Surg 83:246–248PubMedCrossRef Sanders A, Buchan N (2013) Infection-related hospital admissions after transrectal biopsy of the prostate. ANZ J Surg 83:246–248PubMedCrossRef
15.
Zurück zum Zitat Rajgopal R, Wang Y, Faber KJ, Izawa JI (2012) Vertebral osteomyelitis following transrectal ultrasound-guided biopsy of the prostate. Can Urol Assoc J 6:E20–E22PubMedCentralPubMed Rajgopal R, Wang Y, Faber KJ, Izawa JI (2012) Vertebral osteomyelitis following transrectal ultrasound-guided biopsy of the prostate. Can Urol Assoc J 6:E20–E22PubMedCentralPubMed
16.
Zurück zum Zitat Williamson DA, Roberts SA, Paterson DL, Sidjabat H, Silvey A, Masters J, Rice M, Freeman JT (2012) Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 54:1406–1412PubMedCrossRef Williamson DA, Roberts SA, Paterson DL, Sidjabat H, Silvey A, Masters J, Rice M, Freeman JT (2012) Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 54:1406–1412PubMedCrossRef
17.
Zurück zum Zitat Rogers BR, Batura D, Gopal Rao G (2013) Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: our experience in North West London. Clin Infect Dis 56:465–466PubMedCrossRef Rogers BR, Batura D, Gopal Rao G (2013) Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: our experience in North West London. Clin Infect Dis 56:465–466PubMedCrossRef
18.
Zurück zum Zitat Hernandez-Graulau JM (2009) Editorial comment. Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy. Urology 74:338–339PubMedCrossRef Hernandez-Graulau JM (2009) Editorial comment. Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy. Urology 74:338–339PubMedCrossRef
19.
Zurück zum Zitat Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J (2012) Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy–should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 18:575–581PubMedCrossRef Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J (2012) Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy–should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 18:575–581PubMedCrossRef
20.
Zurück zum Zitat Liss MA, Peeples AN, Peterson EM (2011) Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy. J Clin Microbiol 49:1116–1118PubMedCentralPubMedCrossRef Liss MA, Peeples AN, Peterson EM (2011) Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy. J Clin Microbiol 49:1116–1118PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Batura D, Gopal Rao G, Nielsen PB, Charlett A (2011) Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates. BJU Int 107:760–764PubMedCrossRef Batura D, Gopal Rao G, Nielsen PB, Charlett A (2011) Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates. BJU Int 107:760–764PubMedCrossRef
22.
Zurück zum Zitat Adibi M, Hornberger B, Bhat D, Raj G, Roehrborn CG, Lotan Y (2013) Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. J Urol 189:535–540PubMedCrossRef Adibi M, Hornberger B, Bhat D, Raj G, Roehrborn CG, Lotan Y (2013) Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. J Urol 189:535–540PubMedCrossRef
23.
Zurück zum Zitat Ho HS, Ng LG, Tan YH, Yeo M, Cheng CW (2009) Intramuscular gentamicin improves the efficacy of ciprofloxacin as an antibiotic prophylaxis for transrectal prostate biopsy. Ann Acad Med Singap 38:212–216PubMed Ho HS, Ng LG, Tan YH, Yeo M, Cheng CW (2009) Intramuscular gentamicin improves the efficacy of ciprofloxacin as an antibiotic prophylaxis for transrectal prostate biopsy. Ann Acad Med Singap 38:212–216PubMed
24.
Zurück zum Zitat Goto T, Makinose S, Ohi Y, Yamauchi D, Kayajima T, Nagayama K, Hayami H (1998) Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. Int J Urol 5:243–246PubMedCrossRef Goto T, Makinose S, Ohi Y, Yamauchi D, Kayajima T, Nagayama K, Hayami H (1998) Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. Int J Urol 5:243–246PubMedCrossRef
25.
Zurück zum Zitat Briffau R, Coloby P, Bruyere F, Ouaki F, Pires C, Dore B, Irani J (2009) One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography-guided prostate biopsy. BJU Int 103:1069–1073CrossRef Briffau R, Coloby P, Bruyere F, Ouaki F, Pires C, Dore B, Irani J (2009) One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography-guided prostate biopsy. BJU Int 103:1069–1073CrossRef
26.
Zurück zum Zitat Hori S, Sengupta A, Joannides A, Balogun-Ojuri B, Tilley R, McLoughlin J (2010) Changing antibiotic prophylaxis for transrectal ultrasound-guided prostate biopsies: are we putting our patients at risk? BJU Int 106:1298–1302PubMedCrossRef Hori S, Sengupta A, Joannides A, Balogun-Ojuri B, Tilley R, McLoughlin J (2010) Changing antibiotic prophylaxis for transrectal ultrasound-guided prostate biopsies: are we putting our patients at risk? BJU Int 106:1298–1302PubMedCrossRef
27.
Zurück zum Zitat Bradley LA, Palomaki GE, Gutman S Samson D, Aronson N (2013) Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol (Epub ahead of print). doi:10.1016/j.juro.2013.02.005 Bradley LA, Palomaki GE, Gutman S Samson D, Aronson N (2013) Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol (Epub ahead of print). doi:10.​1016/​j.​juro.​2013.​02.​005
28.
Zurück zum Zitat Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ (2013) Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies. J Urol 189:1697–1701PubMedCentralPubMedCrossRef Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ (2013) Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies. J Urol 189:1697–1701PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M, Malavaud B (2012) Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 62:986–996PubMedCrossRef Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M, Malavaud B (2012) Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 62:986–996PubMedCrossRef
30.
Zurück zum Zitat Kirby R, Fitzpatrick JM (2012) Optimising repeat prostate biopsy decisions and procedures. BJU Int 109:1750–1754PubMedCrossRef Kirby R, Fitzpatrick JM (2012) Optimising repeat prostate biopsy decisions and procedures. BJU Int 109:1750–1754PubMedCrossRef
31.
Zurück zum Zitat Lorber G, Duvdevani M, Friedman M, Lavy E, Landau EH, Gofrit ON, Pode D, Steinberg D (2013) Sustained-release antibacterial varnish-coated biopsy needle for reduction of infection rates following prostate biopsy-in vitro model. J Endourol 27:277–283PubMedCrossRef Lorber G, Duvdevani M, Friedman M, Lavy E, Landau EH, Gofrit ON, Pode D, Steinberg D (2013) Sustained-release antibacterial varnish-coated biopsy needle for reduction of infection rates following prostate biopsy-in vitro model. J Endourol 27:277–283PubMedCrossRef
Metadaten
Titel
Emergency hospital admissions attributable to infective complications of prostate biopsy despite appropriate prophylaxis: need for additional infection prevention strategies?
verfasst von
G. Gopal Rao
Deepak Batura
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 2/2014
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-013-0529-5

Weitere Artikel der Ausgabe 2/2014

International Urology and Nephrology 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.